ClinicalTrials.gg
Not yet recruitingNCT07883369Updated Oct 20, 2026

Development and Evaluation of a Disease-oriented Scenario Game to Promote ACP Among Older Adults and Family Caregivers

An interventional study of tabletop game and ACP Exercise Book in Heart Failure, Older Adults (65 Years and Older) and Family Caregivers, sponsored by Taipei Veterans General Hospital, Taiwan. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Supportive care

Updated Oct 20, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Current advance care planning (ACP) tabletop games mostly focus on exploring "personal values." While a few explore care preferences through "hypothetical scenarios," they are not disease-oriented, which can create discrepancies between the scenarios or medical treatments and the patient's actual condition and may fail to capture the patient's true preferences. A systematic review found that disease-oriented ACP interventions effectively capture patients' and their families' preferences for medical treatments because they closely reflect the patient's actual disease progression. However, no disease-oriented scenario games are currently available. Therefore, this study, using heart failure as an example, aims to develop and evaluate the impact of disease-oriented scenario games on older adults and family caregivers in ACP.

02

Conditions studied

  • Heart Failure
  • Older Adults (65 Years and Older)
  • Family Caregivers
  • Life Support Treatment
  • Tabletop Game

Browse trials for

03

In context

Heart Failure

5,801 studies on the registry are indexed under Heart Failure; 1,222 are open to participants now.

This study's planned enrollment of 164 is above the median of 72 across 3,790 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older adults aged 65 years or older with heart failure and their family caregivers.
  • Older adults with heart failure are defined as those with ICD-10 codes, and the first three digits of the older adults' ICD code must be I50.
  • Family caregivers must be over 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Severe intellectual disability or inability to understand the research instructions or explanations provided by the researchers.
  • Inability to communicate in either Mandarin or Taiwanese.
  • Severe sensory or expressive impairments (e.g., visual or auditory impairments or aphasia).
  • Older adults with heart failure or whose family caregivers refuse to participate.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Tabletop game

    participate tabletop game

    Behavioral: tabletop game

  • Active comparator
    ACP Exercise Book

    receive ACP Exercise Book

    Behavioral: ACP Exercise Book

Interventions

  • Behavioraltabletop game

    Using tabletop games to promote consistency in medical treatment preferences between older adults with heart failure and their family caregivers.

  • BehavioralACP Exercise Book

    Using ACP Exercise Book

06

What researchers measure

Primary outcomes

  1. The Questionnaire on Life Support Preferences for Heart Failure Patients (QLSP-HF)

    The questionnaire has 30 items and covers three scenarios and ten medical treatments. The scenarios include current health status, end-stage heart failure, and end-stage heart failure with loss of consciousness. The ten medical treatments assessed are antibiotics, inotropes, nasogastric tube feeding, intravenous fluids, cardiopulmonary resuscitation, ventilator support, dialysis, implantable cardioverter-defibrillators (ICDs), left ventricular assist device (LVAD), and heart transplantation. We use a 5-point Likert scale ranging from 1 (absolutely do not want) to 5 (absolutely want), yielding total scores from 30 to 150. Higher scores reflect a stronger preference for life-sustaining treatment.

    Time frame: Baseline, Post-intervention immediately, Post-intervention one month

Secondary outcomes

  1. advance care planning (ACP) attitudes

    The attitude section includes 12 questions about participants' feelings toward implementing ACP. A 5-point Likert scale is used, with scores ranging from "strongly disagree (1 point)" to "strongly agree (5 points)". The higher the total attitude score, the more positive the attitude towards ACP.

    Time frame: Baseline, Post-intervention immediately, Post-intervention one month

  2. advance care planning (ACP) behavioral intention

    The behavioral intention section consists of 6 questions that concern the likelihood of implementing ACP in the future. These questions cover discussing future medical decisions with family, friends, or healthcare professionals; participating in ACP consultations; and signing advance directives (ADs). The scoring system ranges from "very unlikely (1 point)" to "very likely (5 points)". The higher the total score for behavioral intention, the more positive the behavioral intention for ACP.

    Time frame: Baseline, Post-intervention immediately, Post-intervention one month

  3. State-Trait Anxiety Inventory- State Anxiety Scale (STAI-S)

    STAI-S is used to measure an individual's current anxiety level. It uses a 4-point Likert scale, ranging from "almost none (1 point)" to "almost all (4 points)", with a score range of 20 to 80 points; the higher the score, the higher the level of anxiety.

    Time frame: Baseline, Post-intervention immediately, Post-intervention one month

07

Study locations

1 site
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 1,018 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 14 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 31 months; a quarter within 16 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 20, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07883369
Collaborators
National Science and Technology Council, Taiwan
Responsible party
Cheng, Hui- Chuan (Deputy Director, Taipei Veterans General Hospital, Taiwan) — Principal investigator
First posted
Oct 20, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Li-Shan Ke, PhD
Contact
lske333@gmail.com
886-28227101 ext. 3188
Li-Shan Ke, PhD
principal investigator · National Taipei University of Nursing and Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion